Polynovo Ltd (ASX: PNV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Polynovo Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.35 billion
P/E Ratio 260.00
Dividend Yield 0.00%
Shares Outstanding 690.84 million
Earnings per share 0.008
Dividend per share N/A
Year To Date Return 17.82%
Earnings Yield 0.38%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Polynovo Ltd (ASX: PNV)
    Latest News

    a woman
    Share Gainers

    Why the PolyNovo share price has rocketed almost 200% higher in 12 months

    The PolyNovo Ltd (ASX:PNV) share price has almost tripled in value in 12 months. Here's why...

    Read more »

    a woman
    Share Gainers

    3 high growth shares climbing fast in 2019

    A2 Milk Company Ltd (ASX: A2M), Afterpay Touch Group Ltd (ASX: APT) and Polynovo Ltd (ASX: PNV) are three stocks which have outperformed…

    Read more »

    a woman
    Share Market News

    PolyNovo Limited posts first-half sales growth of 319%

    PolyNovo Limited (ASX: PNV) is a biotechnology company which treats wounds using its polymer technology NovoSorb.

    Read more »

    a woman
    ⏸️ Investing

    3 disruptive small caps finishing the trading week at 52-week highs

    These 3 small cap companies must be doing something right, with all of them hitting a 52-week share price high…

    Read more »

    a woman
    ⏸️ Investing

    Insiders have been buying these 3 ASX shares

    Insiders have been buying the shares of Harvey Norman Holdings Limited (ASX:HVN) and two other ASX shares...

    Read more »

    a woman
    ⏸️ Investing

    10 of the cheapest shares on the ASX: March update

    Finding the cheapest companies trading on the ASX can be difficult. Here is a March update to the list of…

    Read more »

    Frequently Asked Questions

    The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX  on 26 November 1998 and is headquartered in Melbourne.

    No, the company does not historically pay dividends.

    PNV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Polynovo Ltd

    PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.

    NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.

    PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.

    PNV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $1.95 $-0.06 -2.99% 1,600,830 $2.00 $2.02 $1.94
    19 Dec 2024 $2.01 $-0.11 -5.19% 2,538,423 $2.05 $2.07 $1.98
    18 Dec 2024 $2.12 $0.03 1.44% 1,267,359 $2.09 $2.21 $2.08
    17 Dec 2024 $2.09 $0.02 0.97% 758,417 $2.08 $2.10 $2.06
    16 Dec 2024 $2.07 $0.00 0.00% 1,033,671 $2.06 $2.09 $2.03
    13 Dec 2024 $2.07 $-0.04 -1.90% 1,684,060 $2.08 $2.09 $2.01
    12 Dec 2024 $2.11 $-0.01 -0.47% 1,018,595 $2.12 $2.13 $2.09
    11 Dec 2024 $2.12 $-0.03 -1.40% 1,013,997 $2.13 $2.15 $2.08
    10 Dec 2024 $2.15 $-0.08 -3.59% 1,536,886 $2.26 $2.28 $2.15
    09 Dec 2024 $2.23 $0.01 0.45% 707,727 $2.21 $2.27 $2.21
    06 Dec 2024 $2.22 $-0.04 -1.77% 678,528 $2.25 $2.27 $2.21
    05 Dec 2024 $2.26 $0.04 1.80% 842,963 $2.24 $2.29 $2.21
    04 Dec 2024 $2.22 $-0.03 -1.33% 787,704 $2.20 $2.24 $2.19
    03 Dec 2024 $2.25 $0.06 2.74% 707,985 $2.23 $2.27 $2.22
    02 Dec 2024 $2.19 $-0.01 -0.45% 679,307 $2.22 $2.22 $2.17
    29 Nov 2024 $2.20 $0.04 1.85% 857,101 $2.22 $2.23 $2.16
    28 Nov 2024 $2.16 $0.02 0.93% 1,207,910 $2.17 $2.23 $2.15
    27 Nov 2024 $2.14 $0.08 3.88% 1,480,156 $2.09 $2.16 $2.04
    26 Nov 2024 $2.06 $0.02 0.98% 1,628,790 $2.04 $2.09 $2.03
    25 Nov 2024 $2.04 $0.06 3.03% 2,540,301 $2.02 $2.04 $2.00

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    30 Sep 2024 Andrew Lumsden Sell 50,000 $130,915
    On-market trade.
    26 Sep 2024 Leon Hoare Sell 100,000 $260,839
    On-market trade. As per announcement on 02-01-2024
    13 Sep 2024 Bruce Rathie Sell 750,000 $1,886,900
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive DirectorNon-Executive Chairman Feb 2014
    Mr Williams is a director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has experience advising companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
    Dr Robyn Elliott Non-Executive Director Oct 2019
    Dr Elliott has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott was Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery. Dr Elliott is a member of the Risk Committee.
    Mr Andrew Stuart Lumsden Non-Executive Director Jun 2021
    Mr Lumsden has more than 20 years of experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers. Mr Lumsden is the Chair of the Risk Committee.
    Mr Leon Hoare Non-Executive Director Jan 2016
    Mr Hoare has expertise across multiple Life Sciences sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly is an IP and business development professional with more than 30 years of local and international experience. She has been on the Board of the Institute of Patent and Trademark Attorneys of Australia for over a decade. Ms Emmanuel-Donnelly was Executive Manager of Business Development and Commercial at the CSIRO, was in-house IP Counsel for Unilever in the U.K., and practiced as a patent and trademark attorney for Wilson Gunn.
    Mr Lior Harel Company SecretaryGeneral Counsel May 2024
    -
    Mr Swami Raote Chief Executive Officer Jul 2022
    -
    Swami Raote Chief Executive Officer
    -
    Jan Gielen Chief Financial Officer
    -
    Philip Scorgie Chief Information Officer
    -
    Joseph Amaral Chief Medical Officer (part-time)
    -
    Ingrid Anderson Chief People Officer
    -
    David McQuillan Chief Technical and Scientific Officer
    -
    Lior Harel Company SecretaryGeneral Counsel
    -
    David Morris President Asia Pacific
    -
    Edward Graubart President North America
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 96,149,727 13.93%
    J P Morgan Nominees Australia Pty Limited 80,078,534 11.60%
    Citicorp Nominees Pty Limited 37,720,578 5.46%
    Moggs Creek Pty Ltd (Moggs Creek Super A/C) 19,010,112 2.75%
    Lateral Innovations Pty Ltd (Trust A/C 10,924,103 1.58%
    Mr Anthony Shane Kittel Mrs Michele Therese Kittel (Kittel Family Super A/C) 8,050,000 1.17%
    Bnp Paribas Noms Pty Ltd 7,622,413 1.10%
    National Nominees Limited 6,653,041 0.96%
    Netwealth Investments Limited (Wrap Services A/C) 5,394,880 0.74%
    BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) 4,533,452 0.66%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,414,903 0.64%
    Commonwealth Scientific And Industrial Research Organisation 4,081,250 0.59%
    Mrs Li-Hsien Tsai 3,955,424 0.57%
    Mr David Kenley 3,755,000 0.54%
    Mr Paul Gerard Brennan 3,569,796 0.52%
    Mr Matthew James Avery 3,439,332 0.50%
    Mr David Kenley i 3,139,855 0.45%
    Dr Marcus James Dermot Wagstaff Mrs Lara Kate Wagstaff 3,072,166 0.45%
    Mr Evan Philip Clucas Ms Leanne Jane Weston (Kuranga Nursery Super A/C) 2,931,149 0.42%
    Mr Chris Dawborn (Haskali Super Fund A/C) 2,870,271 0.42%

    Profile

    since

    Note